Skip to main content
logo
Myriad Genetics, Inc. (MYGN)
NASDAQ: MYGN · Real-Time Price · USD
6.75
+0.29 (4.49%)
Nov 5, 2025, 12:43 PM EST - Market open

Revenue by Product

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2023FY 2022FY 2021FY 2020FY 20192014 - 2018
Period Ending
Dec '23 Dec '22 Dec '21 Jun '20 Jun '19 2014 - 2018
Hereditary Cancers
327.80M
Log In
Log In
Log In
Log In
Upgrade
Hereditary Cancers Growth
7.30%
Log In
Log In
Log In
Log In
Upgrade
Prenatal
151.30M
Log In
Log In
Log In
Log In
Upgrade
Prenatal Growth
29.98%
Log In
Log In
Log In
Log In
Upgrade
Pharmacogenomics
138.50M
Log In
Log In
Log In
Log In
Upgrade
Pharmacogenomics Growth
8.54%
Log In
Log In
Log In
Log In
Upgrade
Tumor Profiling
135.60M
Log In
Log In
Log In
Log In
Upgrade
Tumor Profiling Growth
5.44%
Log In
Log In
Log In
Log In
Upgrade
Autoimmune
-
Log In
Log In
Log In
Log In
Upgrade
Autoimmune Growth
-
Log In
Log In
Log In
Log In
Upgrade
Pharmaceutical and Clinical Service
-
Log In
Log In
Log In
Log In
Upgrade
Other
-
Log In
Log In
Log In
Log In
Upgrade
Other Growth
-
Log In
Log In
Log In
Log In
Upgrade
Diagnostics
-
Log In
Log In
Log In
Log In
Upgrade
Diagnostics Growth
-
Log In
Log In
Log In
Log In
Upgrade

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2023FY 2022FY 2021FY 2020FY 20192014 - 2018
Period Ending
Dec '23 Dec '22 Dec '21 Jun '20 Jun '19 2014 - 2018
United States
671.70M
Log In
Log In
Log In
Log In
Upgrade
United States Growth
13.56%
Log In
Log In
Log In
Log In
Upgrade
Rest of World
81.50M
Log In
Log In
Log In
Log In
Upgrade
Rest of World Growth
-6.21%
Log In
Log In
Log In
Log In
Upgrade